SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus.
Adolescent
Biomarkers
/ metabolism
Child
Child, Preschool
Disease Progression
Female
Flow Cytometry
/ methods
Humans
Lupus Erythematosus, Systemic
/ genetics
Male
Minimal Clinically Important Difference
Monocytes
/ metabolism
Retrospective Studies
Sialic Acid Binding Ig-like Lectin 1
/ genetics
Symptom Flare Up
Pediatric systemic lupus erythematosus
SIGLEC1
SLEDAI
biomarker
childhood
hydroxychloroquine
type 1 interferon
Journal
Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
22
10
2020
medline:
27
7
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
To analyse the validity of membrane-bound SIGLEC1 (CD169) as a sensitive biomarker for monitoring disease activity in pediatric systemic lupus erythematosus (SLE). 27 children and adolescents with SLE were followed for a mean of 13.5 months. During consecutive routine visits SLEDAI-2k, C3, C4 and ds-DNA values were determined. Additionally, expression of SIGLEC1 on monocytes was determined by flow cytometry. The amount of PE-labelled CD169 mAb bound per monocyte was analyzed using QuantiBRITE™ PE tubes. Associations between biomarkers and the clinical course were investigated by regression analysis. In general, SIGLEC1 expression is high on SLE-derived monocytes (mean 6 359 (SD 6 056) molecules/monocyte, cut-off 2 500 molecules/monocyte), all patients with newly diagnosed SLE exhibit elevated expression (mean 13366 (SD 7 750) molecules/monocyte). Changes (Δ) in SIGLEC1 levels during the clinical course is the only biomarker that significantly correlates with the change in SLEDAI-2k (beta SIGLEC1 expression on monocytes is a sensitive biomarker for adjusting disease activity in childhood SLE and represents a promising and easily applicable tool for disease monitoring.
Sections du résumé
BACKGROUND
BACKGROUND
To analyse the validity of membrane-bound SIGLEC1 (CD169) as a sensitive biomarker for monitoring disease activity in pediatric systemic lupus erythematosus (SLE).
METHODS
METHODS
27 children and adolescents with SLE were followed for a mean of 13.5 months. During consecutive routine visits SLEDAI-2k, C3, C4 and ds-DNA values were determined. Additionally, expression of SIGLEC1 on monocytes was determined by flow cytometry. The amount of PE-labelled CD169 mAb bound per monocyte was analyzed using QuantiBRITE™ PE tubes. Associations between biomarkers and the clinical course were investigated by regression analysis.
RESULTS
RESULTS
In general, SIGLEC1 expression is high on SLE-derived monocytes (mean 6 359 (SD 6 056) molecules/monocyte, cut-off 2 500 molecules/monocyte), all patients with newly diagnosed SLE exhibit elevated expression (mean 13366 (SD 7 750) molecules/monocyte). Changes (Δ) in SIGLEC1 levels during the clinical course is the only biomarker that significantly correlates with the change in SLEDAI-2k (beta
CONCLUSIONS
CONCLUSIONS
SIGLEC1 expression on monocytes is a sensitive biomarker for adjusting disease activity in childhood SLE and represents a promising and easily applicable tool for disease monitoring.
Identifiants
pubmed: 33081587
doi: 10.1177/0961203320965699
pmc: PMC7684796
doi:
Substances chimiques
Biomarkers
0
SIGLEC1 protein, human
0
Sialic Acid Binding Ig-like Lectin 1
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1914-1925Références
Medicine (Baltimore). 2006 May;85(3):147-56
pubmed: 16721257
Immunity. 2006 Sep;25(3):383-92
pubmed: 16979570
J Rheumatol. 2000 Jun;27(6):1421-8
pubmed: 10852264
Clin Exp Immunol. 2009 Apr;156(1):134-40
pubmed: 19175619
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
J Mol Med (Berl). 2016 Oct;94(10):1103-1110
pubmed: 27094810
Lancet. 2014 Nov 22;384(9957):1878-1888
pubmed: 24881804
Ann Rheum Dis. 1989 Jun;48(6):455-60
pubmed: 2742400
Arthritis Rheum. 2008 Feb;58(2):556-62
pubmed: 18240232
Ann Rheum Dis. 2010 Jul;69(7):1269-74
pubmed: 19892750
BMC Med Res Methodol. 2009 Sep 10;9:63
pubmed: 19744332
Clin Exp Immunol. 1987 Dec;70(3):562-9
pubmed: 2449306
Am Psychol. 2003 Jan;58(1):78-9
pubmed: 12674822
Arthritis Rheum. 2008 Apr;58(4):1136-45
pubmed: 18383365
Arthritis Rheum. 1992 Jun;35(6):630-40
pubmed: 1599520
Control Clin Trials. 1989 Dec;10(4):407-15
pubmed: 2691207
J Immunol. 2011 Apr 15;186(8):4794-804
pubmed: 21398612
J Rheumatol. 2000 Feb;27(2):377-9
pubmed: 10685800
Arthritis Rheum. 2008 Jul;58(7):2113-9
pubmed: 18576315
Rheumatology (Oxford). 2017 Sep 1;56(9):1618-1626
pubmed: 28859328
Curr Rheumatol Rep. 2015 Jan;17(1):471
pubmed: 25475594
Lupus. 2009 Oct;18(11):980-9
pubmed: 19762399
Ann Rheum Dis. 2009 Sep;68(9):1440-6
pubmed: 18772188
Arthritis Rheum. 2006 Oct;54(10):3284-90
pubmed: 17009263
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
Lancet. 2013 Aug 31;382(9894):819-31
pubmed: 23993191
Arthritis Res Ther. 2018 Jul 27;20(1):152
pubmed: 30053827
Nature. 2010 Jun 17;465(7300):937-41
pubmed: 20559388
Arthritis Rheum. 2009 Oct;60(10):3098-107
pubmed: 19790071
Nat Rev Rheumatol. 2010 Jan;6(1):40-9
pubmed: 20046205
Hum Genomics Proteomics. 2009 Nov 17;2009:
pubmed: 20948567
Rheumatology (Oxford). 2007 Jul;46(7):1052-6
pubmed: 17500073
Ann Rheum Dis. 2013 Oct;72(10):1639-45
pubmed: 23117242
J Pediatr. 2008 Apr;152(4):550-6
pubmed: 18346514
Arthritis Care Res (Hoboken). 2010 Jul;62(7):950-9
pubmed: 20589695
Nat Rev Immunol. 2007 Apr;7(4):255-66
pubmed: 17380156
Lupus. 2000;9(9):664-71
pubmed: 11199920